Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
500 CHF | +194,12% | -.--% | -.--% |
21/05 | Nanobiotix draagt Fase 3 hoofd-hals kanker studie sponsorschap over | MT |
21/05 | Valneva benoemt nieuwe Chief Scientific Officer | MT |
Omzet 2024 * | 88,37 mld. 80,82 mld. 81,58 mld. | Omzet 2025 * | 90,78 mld. 83,02 mld. 83,81 mld. | Marktkapitalisatie | 364 mld. 333 mld. 336 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 22,04 mld. 20,16 mld. 20,35 mld. | Nettowinst (verlies) 2025 * | 23,09 mld. 21,12 mld. 21,32 mld. | EV/omzet 2024 * | 4,04 x |
Nettoliquiditeiten 2024 * | 7 mld. 6,4 mld. 6,46 mld. | Nettoliquiditeiten 2025 * | 21,07 mld. 19,27 mld. 19,46 mld. | EV/omzet 2025 * | 3,78 x |
K/w-verhouding 2024 * |
16,8
x | K/w-verhouding 2025 * |
15,9
x | Werknemers | - |
Dividendrendement 2024 * |
3,19% | Dividendrendement 2025 * |
3,33% | Vrij verhandelbaar | 77,08% |
Recentste transcriptie over Johnson & Johnson
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 01-01-89 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 01-01-98 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 05-11-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 25-04-19 |
D. Davis
BRD | Director/Board Member | 72 | 19-06-14 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 22-10-09 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+37,78% | 723 mld. | |
+31,08% | 598 mld. | |
+19,94% | 331 mld. | |
+5,14% | 288 mld. | |
+16,30% | 244 mld. | |
-4,87% | 208 mld. | |
+9,99% | 210 mld. | |
+9,32% | 169 mld. | |
-0,80% | 162 mld. |